Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Escudier

Showing results (31-40 of 362) with videos related to

Pageof 37
Sort By:
Therapeutic Advances in Medical Oncology|March 28, 2017
Nivolumab in renal cell carcinoma: latest evidence and clinical potentialCamille Mazza, Bernard Escudier, Laurence Albiges
Bulletin Du Cancer|February 22, 2014
[Kidney function and renal cancer surgery]Hassan Izzedine, Arnaud Méjean, Bernard Escudier
The Oncologist|July 19, 2012
Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?Laurence Albiges, Vincent Molinie, Bernard Escudier
Biologics : Targets & Therapy|August 27, 2009
Targeted therapies in the management of renal cell carcinoma: role of bevacizumabBernard Escudier, Jan Cosaert, Sangeeta Jethwa
Expert Review of Anticancer Therapy|December 22, 2018
Sorafenib: key lessons from over 10 years of experienceBernard Escudier, Francis Worden, Masatoshi Kudo
Drugs|September 7, 2018
Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell CarcinomaRonan Flippot, Bernard Escudier, Laurence Albiges
Expert Opinion on Emerging Drugs|May 19, 2015
Emerging tyrosine kinase inhibitors for the treatment of renal cancerRoberto Iacovelli, Laurence Albiges, Bernard Escudier
Critical Reviews in Oncology/Hematology|July 8, 2011
Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical reviewCamillo Porta, Cezary Szczylik, Bernard Escudier
Medical Oncology (Northwood, London, England)|July 2, 2010
Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case studyJoachim Beck, Joaquim Bellmunt, Bernard Escudier
Drugs|April 11, 2013
Optimal management of metastatic renal cell carcinoma: current statusBernard Escudier, Laurence Albiges, Guru Sonpavde
Pageof 37

Showing results (31-40 of 362) with videos related to

Sort By:
Pageof 37
Therapeutic Advances in Medical Oncology|March 28, 2017
Nivolumab in renal cell carcinoma: latest evidence and clinical potentialCamille Mazza, Bernard Escudier, Laurence Albiges
Bulletin Du Cancer|February 22, 2014
[Kidney function and renal cancer surgery]Hassan Izzedine, Arnaud Méjean, Bernard Escudier
The Oncologist|July 19, 2012
Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?Laurence Albiges, Vincent Molinie, Bernard Escudier
Biologics : Targets & Therapy|August 27, 2009
Targeted therapies in the management of renal cell carcinoma: role of bevacizumabBernard Escudier, Jan Cosaert, Sangeeta Jethwa
Expert Review of Anticancer Therapy|December 22, 2018
Sorafenib: key lessons from over 10 years of experienceBernard Escudier, Francis Worden, Masatoshi Kudo
Drugs|September 7, 2018
Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell CarcinomaRonan Flippot, Bernard Escudier, Laurence Albiges
Expert Opinion on Emerging Drugs|May 19, 2015
Emerging tyrosine kinase inhibitors for the treatment of renal cancerRoberto Iacovelli, Laurence Albiges, Bernard Escudier
Critical Reviews in Oncology/Hematology|July 8, 2011
Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical reviewCamillo Porta, Cezary Szczylik, Bernard Escudier
Medical Oncology (Northwood, London, England)|July 2, 2010
Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case studyJoachim Beck, Joaquim Bellmunt, Bernard Escudier
Drugs|April 11, 2013
Optimal management of metastatic renal cell carcinoma: current statusBernard Escudier, Laurence Albiges, Guru Sonpavde
Pageof 37